Cagrilintide vs Survodutide
Both Cagrilintide and Survodutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Cagrilintide
Evidence ACagrilintide (long-acting amylin analog)
A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.
View full Cagrilintide profile →Survodutide
Evidence ASurvodutide (BI 456906)
A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
View full Survodutide profile →Side-by-Side
| Attribute | Cagrilintide | Survodutide |
|---|---|---|
| Evidence Grade | A | A |
| FDA Status | Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress | Not FDA-approved — Phase 3 trials for obesity and MASH |
| Typical Dose | Trial range: 0.16–4.5 mg weekly (subcutaneous) | Trial range: 0.6–6 mg weekly (subcutaneous) |
| Clinics Indexed | 8 | 6 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Cagrilintide
- ✓Amylin pathway weight loss
- ✓Synergy with GLP-1
- ✓Lower-dose tolerability
Key reported benefits — Survodutide
- ✓Weight loss
- ✓MASH resolution
- ✓Glucose control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.